Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan

Yuki Kaneshiro, Atsuhiro Ichihara, Mariyo Sakoda, Asako Kurauchi-Mito, Kenichiro Kinouchi, Hiroshi Itoh

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Hypertension frequently requires combination therapy to attain efficient control to prevent cardiovascular diseases effectively. This study was conducted to determine which add-on treatment is better, namely calcium channel blockers or diuretics, in improving vascular damage. In 70 nondiabetic chronic kidney disease stage 1/2 patients who had been already treated with angiotensin II type 1 receptor blocker valsartan for at least 12 months, amlodipine or hydrochlorothiazide was added to their existing medication. Pulse wave velocity (PWV), intima-media thickness (IMT) of the carotid arteries, urinary albumin excretion (UAE), and 24-hour ambulatory blood pressure (BP) were determined before and 12 months after the start of add-on treatments. Add-on amlodipine and add-on hydrochlorothiazide significantly and similarly decreased 24-hour ambulatory BP by 18 and 19 mm Hg, respectively, PWV by 206 and 184 cm/s, respectively, and UAE, but did not change the IMT. The decreases in BP significantly contributed to the decreases in PWV and UAE and suggested that the decrease in serum cholesterol level brought about by add-on amlodipine also contributed to the decrease in UAE. These results suggest that 12 months of add-on treatment with either amlodipine or hydrochlorothiazide could have beneficial effects in nondiabetic chronic kidney disease stage 1/2 patients already being treated with valsartan.

Original languageEnglish
Pages (from-to)51-58
Number of pages8
JournalKidney and Blood Pressure Research
Volume32
Issue number1
DOIs
Publication statusPublished - 2009 Mar

Fingerprint

Valsartan
Thiazides
Amlodipine
Chronic Renal Insufficiency
Pulse Wave Analysis
Hydrochlorothiazide
Albumins
Blood Pressure
Angiotensin II Type 1 Receptor Blockers
Calcium Channel Blockers
Therapeutics
Carotid Arteries
Diuretics
Blood Vessels
Cardiovascular Diseases
Cholesterol
Hypertension
Serum

Keywords

  • Chronic kidney disease
  • Intima-media thickness
  • Pulse wave velocity
  • Urinary albumin excretion

ASJC Scopus subject areas

  • Nephrology
  • Cardiology and Cardiovascular Medicine

Cite this

Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan. / Kaneshiro, Yuki; Ichihara, Atsuhiro; Sakoda, Mariyo; Kurauchi-Mito, Asako; Kinouchi, Kenichiro; Itoh, Hiroshi.

In: Kidney and Blood Pressure Research, Vol. 32, No. 1, 03.2009, p. 51-58.

Research output: Contribution to journalArticle

Kaneshiro, Yuki ; Ichihara, Atsuhiro ; Sakoda, Mariyo ; Kurauchi-Mito, Asako ; Kinouchi, Kenichiro ; Itoh, Hiroshi. / Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan. In: Kidney and Blood Pressure Research. 2009 ; Vol. 32, No. 1. pp. 51-58.
@article{02427937fc9e4b1d88fb65dff53cf358,
title = "Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan",
abstract = "Hypertension frequently requires combination therapy to attain efficient control to prevent cardiovascular diseases effectively. This study was conducted to determine which add-on treatment is better, namely calcium channel blockers or diuretics, in improving vascular damage. In 70 nondiabetic chronic kidney disease stage 1/2 patients who had been already treated with angiotensin II type 1 receptor blocker valsartan for at least 12 months, amlodipine or hydrochlorothiazide was added to their existing medication. Pulse wave velocity (PWV), intima-media thickness (IMT) of the carotid arteries, urinary albumin excretion (UAE), and 24-hour ambulatory blood pressure (BP) were determined before and 12 months after the start of add-on treatments. Add-on amlodipine and add-on hydrochlorothiazide significantly and similarly decreased 24-hour ambulatory BP by 18 and 19 mm Hg, respectively, PWV by 206 and 184 cm/s, respectively, and UAE, but did not change the IMT. The decreases in BP significantly contributed to the decreases in PWV and UAE and suggested that the decrease in serum cholesterol level brought about by add-on amlodipine also contributed to the decrease in UAE. These results suggest that 12 months of add-on treatment with either amlodipine or hydrochlorothiazide could have beneficial effects in nondiabetic chronic kidney disease stage 1/2 patients already being treated with valsartan.",
keywords = "Chronic kidney disease, Intima-media thickness, Pulse wave velocity, Urinary albumin excretion",
author = "Yuki Kaneshiro and Atsuhiro Ichihara and Mariyo Sakoda and Asako Kurauchi-Mito and Kenichiro Kinouchi and Hiroshi Itoh",
year = "2009",
month = "3",
doi = "10.1159/000205521",
language = "English",
volume = "32",
pages = "51--58",
journal = "Kidney and Blood Pressure Research",
issn = "1420-4096",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan

AU - Kaneshiro, Yuki

AU - Ichihara, Atsuhiro

AU - Sakoda, Mariyo

AU - Kurauchi-Mito, Asako

AU - Kinouchi, Kenichiro

AU - Itoh, Hiroshi

PY - 2009/3

Y1 - 2009/3

N2 - Hypertension frequently requires combination therapy to attain efficient control to prevent cardiovascular diseases effectively. This study was conducted to determine which add-on treatment is better, namely calcium channel blockers or diuretics, in improving vascular damage. In 70 nondiabetic chronic kidney disease stage 1/2 patients who had been already treated with angiotensin II type 1 receptor blocker valsartan for at least 12 months, amlodipine or hydrochlorothiazide was added to their existing medication. Pulse wave velocity (PWV), intima-media thickness (IMT) of the carotid arteries, urinary albumin excretion (UAE), and 24-hour ambulatory blood pressure (BP) were determined before and 12 months after the start of add-on treatments. Add-on amlodipine and add-on hydrochlorothiazide significantly and similarly decreased 24-hour ambulatory BP by 18 and 19 mm Hg, respectively, PWV by 206 and 184 cm/s, respectively, and UAE, but did not change the IMT. The decreases in BP significantly contributed to the decreases in PWV and UAE and suggested that the decrease in serum cholesterol level brought about by add-on amlodipine also contributed to the decrease in UAE. These results suggest that 12 months of add-on treatment with either amlodipine or hydrochlorothiazide could have beneficial effects in nondiabetic chronic kidney disease stage 1/2 patients already being treated with valsartan.

AB - Hypertension frequently requires combination therapy to attain efficient control to prevent cardiovascular diseases effectively. This study was conducted to determine which add-on treatment is better, namely calcium channel blockers or diuretics, in improving vascular damage. In 70 nondiabetic chronic kidney disease stage 1/2 patients who had been already treated with angiotensin II type 1 receptor blocker valsartan for at least 12 months, amlodipine or hydrochlorothiazide was added to their existing medication. Pulse wave velocity (PWV), intima-media thickness (IMT) of the carotid arteries, urinary albumin excretion (UAE), and 24-hour ambulatory blood pressure (BP) were determined before and 12 months after the start of add-on treatments. Add-on amlodipine and add-on hydrochlorothiazide significantly and similarly decreased 24-hour ambulatory BP by 18 and 19 mm Hg, respectively, PWV by 206 and 184 cm/s, respectively, and UAE, but did not change the IMT. The decreases in BP significantly contributed to the decreases in PWV and UAE and suggested that the decrease in serum cholesterol level brought about by add-on amlodipine also contributed to the decrease in UAE. These results suggest that 12 months of add-on treatment with either amlodipine or hydrochlorothiazide could have beneficial effects in nondiabetic chronic kidney disease stage 1/2 patients already being treated with valsartan.

KW - Chronic kidney disease

KW - Intima-media thickness

KW - Pulse wave velocity

KW - Urinary albumin excretion

UR - http://www.scopus.com/inward/record.url?scp=61349142469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349142469&partnerID=8YFLogxK

U2 - 10.1159/000205521

DO - 10.1159/000205521

M3 - Article

VL - 32

SP - 51

EP - 58

JO - Kidney and Blood Pressure Research

JF - Kidney and Blood Pressure Research

SN - 1420-4096

IS - 1

ER -